LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)       0.79  +0.02 (+2.6%)

0.79  +0.02 (+2.6%)

US5393192027 - Common Stock - After market: 0.85 +0.06 (+7.59%)

LIXTE BIOTECHNOLOGY HOLDINGS0.79

NASDAQ:LIXT (2/3/2023, 7:00:03 PM)+0.02 (+2.6%)

After market: 0.85 +0.06 (+7.59%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) N/A N/A Earnings (Next) 03-20 2023-03-20/bmo
Ins Owners 1% Inst Owners 3.9%
Market Cap 13.15M Shares 16.65M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts N/A
IPO 09-21 2007-09-21

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LIXT Daily chart

Company Profile

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The firm has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.

Company Info

LIXTE BIOTECHNOLOGY HOLDINGS

No. 2, 248 Route 25A

East Setauket NEW YORK 11733

P: 13102032902.0

CEO: John S. Kovach

Employees: 3

Website: http://www.lixte.com/

LIXT News

News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!

News Image4 months ago - Lixte Biotechnology Holdings, Inc.LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage...

News Image4 months ago - Lixte Biotechnology Holdings, Inc.LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUPNews Image8 months ago - Lixte Biotechnology Holdings, Inc.LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on...

News Image8 months ago - Lixte Biotechnology Holdings, Inc.LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical...

LIXT Twits

Here you can normally see the latest stock twits on LIXT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example